Cardiac Marker Testing Market

Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028

Report Code: MD 4673 Oct, 2023, by marketsandmarkets.com

The global cardiac marker testing market in terms of revenue was estimated to be worth $4.4 billion in 2023 and is poised to reach $6.9 billion by 2028, growing at a CAGR of 9.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increase in chronic heart conditions and aging population, increasing research & funding initiatives from organizations and worldwide rise in prevalence of cardiovascular diseases are a few drivers that collectively contribute to the growth of the cardiac marker testing industry, and as healthcare technologies continue to evolve, the demand for cardiac marker testing is expected to rise further in the upcoming years. However, challenges for regulatory issues, sampling collection and storage limits the market growth.

Attractive Opportunities in the Cardiac Marker Testing Market

Cardiac Marker Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cardiac Marker Testing Market

Cardiac Marker Testing Market: Market Dynamics

Driver: Increase in prevalence of cardiovascular diseases

The escalating prevalence of cardiovascular diseases stands as a significant driving force in the cardiac marker testing industry. This trend underscores a growing demand for advanced diagnostic solutions, compelling the healthcare industry to invest in innovative cardiac marker testing technologies. As heart-related conditions become more prevalent, the market is witnessing a surge in the adoption of these tests, emphasizing the critical need for accurate and efficient diagnostic tools. This demand, fueled by the rising incidence of cardiovascular diseases, is reshaping the landscape of cardiac marker testing and driving advancements in the sector.

Restraint: Issues related to storage and sampling collection

In epidemiological studies, cardiac biomarkers play a crucial role in investigating various stages of diseases in humans. This process necessitates meticulous handling and storage of valuable biological samples to extract extensive information from limited specimens. Maintaining stringent quality control is imperative to ensure the appropriate storage conditions, preventing data loss. The effectiveness of cardiac biomarker studies utilizing archived specimens heavily relies on the integrity of these samples and the methods employed in their processing, collection, and storage. Technical challenges in both sample collection and storage have the potential to impede the growth of the overall cardiac biomarkers market, particularly in the laboratory-based testing segment.

Opportunity: Emerging markets offering growth opportunities

Rapidly growing economies like India and China present substantial growth prospects in the field of cardiac diagnostics due to the expanding patient base caused by the rising prevalence of cardiovascular diseases in these nations. China has witnessed a significant surge in cardiovascular disease (CVD) due to heightened risk factors like high blood cholesterol, obesity, and diabetes mellitus. The escalating burden of cardiovascular diseases in these emerging economies is set to boost the demand for early disease diagnostics, thereby accelerating the adoption of cardiac marker testing products.

Cardiac Marker Testing Market Ecosystem

Major companies in this market include well-established and financially stable suppliers of cardiac marker testing. Prominent companies in this market include F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMérieux SA (France), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), among several others.

Cardiac Marker Testing Market Ecosystem

Reagents and kits segment of the cardiac marker testing industry to register significant growth rate over the forecast period of 2022-2028

Based on the product, the cardiac marker testing market is segmented into reagents and kits and instruments. Reagents and Kits segment to register a significant growth rate over the forecast period of 2022-2028. The expansion of the market for cardiac marker testing reagents and kits can be credited to the escalating volume of cardiac biomarker tests conducted, driven by the global prevalence of cardiovascular diseases (CVD) and the growing elderly demographic. This surge in demand for swift CVD diagnosis has led to the widespread adoption of rapid cardiac biomarker test kits. Furthermore, the market's growth is further bolstered by the introduction of new cardiac biomarker test kits by industry players.

Troponin I and T segment of the cardiac marker testing industry is the largest biomarker segment in 2022.

Cardiac troponin stands as the preferred biomarker for diagnosing acute myocardial infarction (AMI) due to its exceptional sensitivity and specificity. Recently, the cardiac marker testing market has witnessed the introduction of several high-sensitivity troponin assays, capable of detecting the protein swiftly and at significantly lower levels than standard troponin tests. Additionally, troponin biomarkers play a crucial role in identifying the risk of future heart events, even in asymptomatic individuals. These factors are expected to drive the growth of this segment in the forthcoming years.

Asia-Pacific region of the cardiac marker testing industry is expected to be the highest CAGR during the forecast period.

The cardiac marker testing market is divided into key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the largest market share in the global diagnostic imaging service market. However, the Asia Pacific region is anticipated to exhibit the highest Compound Annual Growth Rate (CAGR) during the forecast period. This growth is primarily attributed to the increasing incidence of cardiovascular diseases (CVD), a rise in testing procedures, improvements in healthcare infrastructure, and the widespread adoption of advanced immunoassay technology by clinical laboratories. Additionally, the market in the Asia Pacific region is set to receive a boost from the growing number of local manufacturers offering cardiac marker testing products and the increasing establishment of diagnostic laboratories in the area.

Cardiac Marker Testing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

As of 2022, prominent players in the market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), DiaSorin (Italy), and Tosoh Corporation (Japan), LSI Medience Corporation (Japan), Quidel Corporation (US), among others.

Scope of the Cardiac Marker Testing Industry:

Report Metric

Details

Market Revenue in 2023

$4.4 billion

Estimated Value by 2028

$6.9 billion

Revenue Rate

Poised to grow at a CAGR of 9.4%

Market Driver

Increase in prevalence of cardiovascular diseases

Market Opportunity

Emerging markets offering growth opportunities

This report has segmented the global cardiac marker testing market to forecast revenue and analyze trends in each of the following submarkets:

By Product Type

  • Reagents and Kits
  • Instruments
    • Chemiluminescence
    • Immunofluorescence
    • ELISA
    • Immunochromatography

By biomarker type

  • Troponin I and T
  • Creatine kinase-MB(CK-MB)
  • Brain Natriuretic peptide (Bnp Or Nt-Probnp)
  • Myoglobin
  • High-sensitivity C-reactive protein(hs-CRP)
  • Other Cardiac Biomarkers

By diseases

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Ischemia

By End User

  • Laboratory Testing Facilities
    • Hospital Labs
    • Reference Labs
    • Contract Testing Labs
  • Point-Of-Care Testing Facilities
  • Academic Institutions

By region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
  • MEA

Recent market Developments of Cardiac Marker Testing Industry

  • In 2023, BD announced that it had received FDA approval for its BD Vacutainer Troponin I Ultra test to be used in point-of-care settings which makes the BD Vacutainer Troponin I Ultra test the first and only FDA-approved point-of-care troponin test for the diagnosis of acute myocardial infarction (AMI).
  • In 2023, Bio-Rad launched the Bio-Plex 2300 Troponin I Assay, a new high-sensitivity troponin I test that can detect cardiac damage earlier than other troponin tests..

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 28)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 REGIONS COVERED
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY 
    1.6 RESEARCH LIMITATIONS 
    1.7 MARKET STAKEHOLDERS 
    1.8 SUMMARY OF CHANGES 
           1.8.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
    2.2 RESEARCH DESIGN 
           2.2.1 SECONDARY RESEARCH
                    FIGURE 1 KEY DATA FROM SECONDARY SOURCES
           2.2.2 PRIMARY RESEARCH
                    2.2.2.1 Primary sources
                    2.2.2.2 Key industry insights
                    2.2.2.3 Breakdown of primaries
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,  DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
          FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.3.1 BOTTOM-UP APPROACH
           2.3.2 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
                    FIGURE 5 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
           2.3.3 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
                    FIGURE 6 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION:  BOTTOM-UP APPROACH
           2.3.4 APPROACH 3: TOP-DOWN APPROACH
           2.3.5 APPROACH 4: PRIMARY INTERVIEWS
                    FIGURE 7 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
    2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ASSESSMENT 
    2.6 STUDY ASSUMPTIONS 
    2.7 RISK ASSESSMENT 
          TABLE 1 LIMITATIONS AND ASSOCIATED RISKS
    2.8 GROWTH RATE ASSUMPTIONS 
    2.9 RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 48)
    FIGURE 9 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,  2023 VS. 2028 (USD MILLION)
    FIGURE 10 CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2023 VS. 2028 (USD MILLION)
    FIGURE 11 CARDIAC MARKER TESTING MARKET, BY INDICATION,  2023 VS. 2028 (USD MILLION)
    FIGURE 12 CARDIAC MARKER TESTING MARKET, BY END USER,  2023 VS. 2028 (USD MILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET
 
4 PREMIUM INSIGHTS (Page No. - 52)
    4.1 CARDIAC MARKER TESTING MARKET OVERVIEW 
          FIGURE 14 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
    4.2 NORTH AMERICA: CARDIAC MARKER TESTING MARKET,  BY COUNTRY AND END USER, 2022 
          FIGURE 15 LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 CARDIAC MARKER TESTING MARKET: REGIONAL MIX 
          FIGURE 16 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
    4.4 CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION 
          FIGURE 18 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.1.1 DRIVERS
                    5.1.1.1 Rising prevalence of cardiovascular diseases
                    5.1.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide
                    5.1.1.3 Growing research and funding initiatives from public and private organizations
                    5.1.1.4 Rising clinical studies for identification of novel cardiac biomarkers
           5.1.2 RESTRAINTS
                    5.1.2.1 Technical issues related to sample collection and storage
                    5.1.2.2 Unfavorable regulatory processes and limited reimbursement structure
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Point-of-care testing with cardiac biomarkers
                    5.1.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases
                    5.1.3.3 Emerging markets
           5.1.4 CHALLENGES
                    5.1.4.1 Challenges associated with biomarker assay validation
    5.2 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING MARKET
                    TABLE 2 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%)
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 3 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 REGULATORY ANALYSIS 
           5.4.1 US
                    TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
           5.4.2 EUROPE
                    TABLE 5 EUROPE: CLASSIFICATION OF IVD DEVICES
           5.4.3 JAPAN
                    TABLE 6 JAPAN: CLASSIFICATION OF IVD REAGENTS
                    TABLE 7 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    5.5 REIMBURSEMENT SCENARIO 
          TABLE 8 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS
    5.6 ECOSYSTEM MAPPING 
    5.7 VALUE CHAIN ANALYSIS 
           5.7.1 RESEARCH & DEVELOPMENT
           5.7.2 PROCUREMENT AND PRODUCT DEVELOPMENT
           5.7.3 MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES
                    FIGURE 20 VALUE CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET
    5.8 SUPPLY CHAIN ANALYSIS 
           5.8.1 PROMINENT COMPANIES
           5.8.2 SMALL & MEDIUM-SIZED COMPANIES
           5.8.3 END USERS
                    FIGURE 21 SUPPLY CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET
    5.9 PRICING ANALYSIS 
          TABLE 9 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER TROPONIN I AND T TEST KITS, 2021
          TABLE 10 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER BPN AND NT-PROBNP  TEST KITS, 2021
          TABLE 11 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER MYOGLOBIN TEST KITS, 2021
          TABLE 12 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER CK-MB TEST KITS, 2022
          TABLE 13 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER C-REACTIVE PROTEIN  (HS-CRP) TEST KITS, 2022
          TABLE 14 AVERAGE SELLING PRICE TREND OF CARDIAC MARKER TEST KITS, BY COUNTRY,  2021–2023 (USD)
    5.10 PATENT ANALYSIS 
           FIGURE 22 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING, JANUARY 2012–SEPTEMBER 2022
           FIGURE 23 TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING,  JANUARY 2012–SEPTEMBER 2022
    5.11 TRADE ANALYSIS 
           TABLE 15 IMPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822),  BY COUNTRY, 2018–2022 (USD THOUSAND)
           TABLE 16 EXPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018–2022 (USD THOUSAND)
    5.12 CASE STUDIES 
           TABLE 17 CASE STUDY: BREAKTHROUGH IN ACUTE MYOCARDIAL INFARCTION DIAGNOSIS WITH HIGH-SENSITIVITY TROPONIN I ASSAYS
    5.13 KEY CONFERENCES AND EVENTS, 2023–2024 
           TABLE 18 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023–2024
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 
           FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
    5.15 IMPACT OF RECESSION ON CARDIAC MARKER TESTING MARKET 
 
6 CARDIAC MARKER TESTING MARKET, BY PRODUCT (Page No. - 78)
    6.1 INTRODUCTION 
          TABLE 19 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 REAGENTS & KITS 
           6.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND
                    TABLE 20 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                    TABLE 21 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY REGION,  2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
          TABLE 22 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE,  2021–2028 (USD MILLION)
          TABLE 23 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
          TABLE 24 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION,  2021–2028 (USD MILLION)
           6.3.1 CHEMILUMINESCENCE
                    6.3.1.1 Most preferred method for quantifying cardiac biomarkers
                                TABLE 25 CHEMILUMINESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                                TABLE 26 CHEMILUMINESCENCE INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.3.2 IMMUNOFLUORESCENCE
                    6.3.2.1 Demand for stable and safer reagents to support market growth
                                TABLE 27 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                                TABLE 28 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY REGION,  2021–2028 (USD MILLION)
           6.3.3 ELISA
                    6.3.3.1 Long shelf life and ease of use to propel growth
                                TABLE 29 ELISA INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)
                                TABLE 30 ELISA INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.3.4 IMMUNOCHROMATOGRAPHY
                    6.3.4.1 Increasing use in point-of-care settings to propel adoption
                                TABLE 31 IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                                TABLE 32 IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY REGION,  2021–2028 (USD MILLION)
 
7 CARDIAC MARKER TESTING MARKET, BY INDICATION (Page No. - 88)
    7.1 INTRODUCTION 
          TABLE 33 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION)
    7.2 MYOCARDIAL INFARCTION 
           7.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION TO DRIVE MARKET
                    TABLE 34 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION,  2021–2028 (USD MILLION)
    7.3 CONGESTIVE HEART FAILURE 
           7.3.1 INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH
                    TABLE 35 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2021–2028 (USD MILLION)
    7.4 ACUTE CORONARY SYNDROME 
           7.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS
                    TABLE 36 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2021–2028 (USD MILLION)
    7.5 ATHEROSCLEROSIS 
           7.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET
                    TABLE 37 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2021–2028 (USD MILLION)
    7.6 ISCHEMIA 
           7.6.1 INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS
                    TABLE 38 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION,  2021–2028 (USD MILLION)
 
8 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE (Page No. - 95)
    8.1 INTRODUCTION 
          TABLE 39 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)
    8.2 TROPONIN I AND T 
           8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET
                    TABLE 40 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY INDICATION,  2021–2028 (USD MILLION)
                    TABLE 41 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY END USER,  2021–2028 (USD MILLION)
                    TABLE 42 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY REGION,  2021–2028 (USD MILLION)
    8.3 CREATINE KINASE-MB 
           8.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH
                    TABLE 43 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY INDICATION,  2021–2028 (USD MILLION)
                    TABLE 44 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY END USER,  2021–2028 (USD MILLION)
                    TABLE 45 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY REGION,  2021–2028 (USD MILLION)
    8.4 BRAIN NATRIURETIC PEPTIDE 
           8.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION
                    TABLE 46 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY INDICATION, 2021–2028 (USD MILLION)
                    TABLE 47 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2021–2028 (USD MILLION)
                    TABLE 48 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2021–2028 (USD MILLION)
    8.5 MYOGLOBIN 
           8.5.1 USED TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS
                    TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY INDICATION,  2021–2028 (USD MILLION)
                    TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER,  2021–2028 (USD MILLION)
                    TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION,  2021–2028 (USD MILLION)
    8.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN 
           8.6.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION
                    TABLE 52 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY INDICATION, 2021–2028 (USD MILLION)
                    TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN,  BY END USER, 2021–2028 (USD MILLION)
                    TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN,  BY REGION, 2021–2028 (USD MILLION)
    8.7 OTHER CARDIAC BIOMARKERS 
          TABLE 55 OTHER CARDIAC BIOMARKERS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
          TABLE 56 OTHER CARDIAC BIOMARKERS MARKET, BY END USER, 2021–2028 (USD MILLION)
          TABLE 57 OTHER CARDIAC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION)
 
9 CARDIAC MARKER TESTING MARKET, BY END USER (Page No. - 108)
    9.1 INTRODUCTION 
          TABLE 58 CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 LABORATORY TESTING FACILITIES 
          TABLE 59 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 60 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2021–2028 (USD MILLION)
           9.2.1 HOSPITAL LABORATORIES
                    9.2.1.1 Early diagnosis associated with in-house labs to support market growth
                                TABLE 61 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION,  2021–2028 (USD MILLION)
           9.2.2 REFERENCE LABORATORIES
                    9.2.2.1 Affordable and time-efficient services associated with reference laboratories to drive market
                                TABLE 62 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
           9.2.3 CONTRACT TESTING LABORATORIES
                    9.2.3.1 Ability to perform multiple tests to propel market
                                TABLE 63 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES,  BY REGION, 2021–2028 (USD MILLION)
    9.3 ACADEMIC INSTITUTES 
           9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET
                    TABLE 64 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION,  2021–2028 (USD MILLION)
    9.4 POINT-OF-CARE TESTING FACILITIES 
           9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO PROPEL MARKET
                    TABLE 65 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES,  BY REGION, 2021–2028 (USD MILLION)
 
10 CARDIAC MARKER TESTING MARKET, BY REGION (Page No. - 115)
     10.1 INTRODUCTION 
             TABLE 66 CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 25 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT
                        TABLE 67 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 68 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 69 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 70 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                        TABLE 71 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Growing support from NIH for development of novel cardiac biomarkers to drive market
                                      TABLE 72 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Government initiatives to support market growth
                                      TABLE 73 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: RECESSION IMPACT
                        TABLE 74 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 75 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 76 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE,  2021–2028 (USD MILLION)
                        TABLE 77 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                        TABLE 78 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Favorable government policies to support market growth
                                      TABLE 79 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising geriatric population to drive market
                                      TABLE 80 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.3.4 UK
                        10.3.4.1 Government initiatives to boost adoption of cardiac biomarkers
                                      TABLE 81 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Adoption of advanced diagnostic technologies to drive market
                                      TABLE 82 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing
                                      TABLE 83 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 84 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 26 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT
                        TABLE 85 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 86 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 87 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE,  2021–2028 (USD MILLION)
                        TABLE 88 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                        TABLE 89 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Presence of advanced laboratory facilities to drive market
                                      TABLE 90 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Growing number of independent clinical laboratories to drive demand for cardiac markers
                                      TABLE 91 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Presence of large patient population to drive demand
                                      TABLE 92 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.4.5 AUSTRALIA
                        10.4.5.1 Increasing healthcare expenditure to support market growth
                                      TABLE 93 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             10.4.6 SOUTH KOREA
                        10.4.6.1 Growing number of private hospitals to drive adoption of advanced testing services
                                      TABLE 94 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             10.4.7 REST OF ASIA PACIFIC
                        TABLE 95 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 96 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 97 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 98 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE,  2021–2028 (USD MILLION)
                        TABLE 99 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                        TABLE 100 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.5.2 BRAZIL
                        10.5.2.1 Increasing government support for advancements in healthcare to support market growth
                                      TABLE 101 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.5.3 MEXICO
                        10.5.3.1 Rising demand for technologically advanced products to drive uptake of cardiac markers
                                      TABLE 102 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             10.5.4 REST OF LATIN AMERICA
                        TABLE 103 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS
             10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 104 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 105 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 106 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE,  2021–2028 (USD MILLION)
                        TABLE 107 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.6.3 GCC COUNTRIES
 
11 COMPETITIVE LANDSCAPE (Page No. - 142)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIAC MARKER TESTING MARKET
     11.3 REVENUE SHARE ANALYSIS 
             FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET, 2018–2022 (USD MILLION)
     11.4 MARKET RANKING ANALYSIS 
     11.5 COMPANY EVALUATION MATRIX 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 29 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX, 2022
     11.6 STARTUP/SME EVALUATION MATRIX 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 30 CARDIAC MARKER TESTING MARKET: STARTUP/SME EVALUATION MATRIX, 2022
     11.7 COMPANY FOOTPRINT 
             TABLE 108 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET
             TABLE 109 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET
             TABLE 110 REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET
     11.8 COMPETITIVE SCENARIOS AND TRENDS 
             TABLE 111 KEY PRODUCT LAUNCHES
             TABLE 112 KEY DEALS
             TABLE 113 OTHER KEY DEVELOPMENTS
 
12 COMPANY PROFILES (Page No. - 157)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 F. HOFFMANN-LA ROCHE AG
                        TABLE 114 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
                        FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022)
             12.1.2 ABBOTT LABORATORIES
                        TABLE 115 ABBOTT LABORATORIES: COMPANY OVERVIEW
                        FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             12.1.3 SIEMENS HEALTHINEERS AG
                        TABLE 116 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
                        FIGURE 33 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
             12.1.4 DANAHER CORPORATION
                        TABLE 117 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.5 BIO-RAD LABORATORIES, INC.
                        TABLE 118 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
                        FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             12.1.6 BIOMÉRIEUX SA
                        TABLE 119 BIOMÉRIEUX SA: COMPANY OVERVIEW
                        FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022)
             12.1.7 BECTON, DICKINSON AND COMPANY
                        TABLE 120 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
                        FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             12.1.8 THERMO FISHER SCIENTIFIC INC.
                        TABLE 121 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             12.1.9 DIASORIN S.P.A.
                        TABLE 122 DIASORIN S.P.A.: COMPANY OVERVIEW
                        FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
             12.1.10 PERKINELMER INC.
                        TABLE 123 PERKINELMER INC.: COMPANY OVERVIEW
                        FIGURE 40 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
             12.1.11 TOSOH CORPORATION
                        TABLE 124 TOSOH CORPORATION: COMPANY OVERVIEW
                        FIGURE 41 TOSOH CORPORATION: COMPANY SNAPSHOT (2023)
             12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION)
                        TABLE 125 LSI MEDIENCE CORPORATION: COMPANY OVERVIEW
                        FIGURE 42 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.13 QUIDEL CORPORATION
                        TABLE 126 QUIDEL CORPORATION: COMPANY OVERVIEW
                        FIGURE 43 QUIDEL CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.14 RANDOX LABORATORIES
                        TABLE 127 RANDOX LABORATORIES: COMPANY OVERVIEW
             12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD.
                        TABLE 128 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW
             12.1.16 BODITECH MED INC.
                        TABLE 129 BODITECH MED INC.: BUSINESS OVERVIEW
             12.1.17 TULIP DIAGNOSTICS (P) LTD.
                        TABLE 130 TULIP DIAGNOSTICS (P) LTD.: BUSINESS OVERVIEW
             12.1.18 BTNX INC.
                        TABLE 131 BTNX INC.: BUSINESS OVERVIEW
             12.1.19 RESPONSE BIOMEDICAL
                        TABLE 132 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW
             12.1.20 ALFA SCIENTIFIC DESIGNS, INC.
                        TABLE 133 ALFA SCIENTIFIC DESIGNS, INC.: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 CTK BIOTECH, INC.
             12.2.2 CREATIVE DIAGNOSTICS
             12.2.3 LIFESIGN LLC
             12.2.4 CARDIOGENICS HOLDINGS INC.
             12.2.5 ATLAS MEDICAL GMBH
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 213)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key market dynamics, key players, competitive landscape, industry trends, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Factiva, Bloomberg Businessweek, and D&B Hoovers), white papers, company house documents, investor presentations, annual reports, and SEC filings of companies. Secondary research was used to identify and collect information useful for the market-oriented, technical, extensive, and commercial study of the cardiac marker testing market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and recent developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

Comprehensive primary research was conducted following an initial understanding of the cardiac marker testing market from secondary research sources. Numerous primary interviews were carried out, encompassing perspectives from both demand (including research institutes, healthcare providers, hospital laboratories, and point-of-care testing facilities) and supply sides (involving developers, manufacturers, and distributors of cardiac marker testing products). The interviewees comprised industry experts from the in vitro diagnostics (IVD) sector, including CEOs, directors, sales heads, VPs and marketing managers from tier 1, 2, and 3 companies providing cardiac biomarker test kits and instruments globally.

Approximately 65% of the interviews were conducted with representatives from the supply side, while the remaining 35% were from the demand side. A rigorous primary research approach was employed to validate the report's contents and bridge any information gaps. Interviews were conducted through telephonic and email communications, where questionnaires were tailored and sent to primary participants based on their convenience.

A breakdown of the primary respondents is provided below:

Cardiac Marker Testing Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2022, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the global cardiac marker testing market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the cardiac marker testing business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as directors, CEOs, and key marketing executives.

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/service providers. This process involved the following steps:

  • Generating a list of major global players operating in the cardiac marker testing market
  • Mapping annual revenues generated by major global players from the cardiac marker testing market segment (or nearest reported product category/ business unit)
  • Revenue mapping of key  players to cover a major share of the global market, as of 2022
  • Extrapolating the global value of the cardiac marker testing industry

Global cardiac marker testing market: Bottom-Up Approach

Cardiac Marker Testing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global cardiac marker testing market: Top-Down Approach

Cardiac Marker Testing Market Size, and Share

Cardiac Marker Testing Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global cardiac marker testing market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the cardiac marker testing market was validated using both top-down and bottom-up approaches.

Market Definition

Cardiac marker testing encompasses a suite of medical diagnostic examinations designed to analyze specific biomolecules, termed cardiac markers, within the bloodstream. These markers, including enzymes, hormones, and proteins, are released when the heart sustains damage or stress, typically in the context of conditions like heart attacks or cardiovascular diseases.

These tests play a crucial role in diagnosing a range of cardiac ailments, gauging the seriousness of cardiac incidents, monitoring patients afflicted with heart conditions, and evaluating the efficacy of treatments. Cardiac marker testing empowers healthcare professionals with accurate and timely diagnostic information, facilitating precise medical interventions and enhancing overall patient outcomes.

Key Stakeholders

  • Product manufacturers, distributors, and suppliers
  • Diagnostic laboratories and point-of-care testing centers
  • Research laboratories and CROs
  • Ambulatory testing centers
  • Contract testing laboratories
  • Academic universities and medical research centers
  • Research and development (R&D) centers
  • Market research and consulting firms

Objectives of the Study

  • To define, describe, and forecast the cardiac marker testing market based on product, procedure, biomarker type, diseases, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the total market.
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To profile the key market players and comprehensively analyze their market shares and core competencies.
  • To forecast the revenue of the market segments with respect to five main regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), the Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa.
  • To track and analyze competitive developments such as new product launches and approvals; agreements, expansions, acquisitions, partnerships; and collaborations in the cardiac marker testing market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global cardiac marker testing market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to 15)

Geographic Analysis

  • Further breakdown of the Rest of Europe cardiac marker testing market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
  • Further breakdown of the Rest of Asia Pacific cardiac marker testing market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
  • Further breakdown of the Rest of the world cardiac marker testing market into Latin America, MEA, and Africa
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 4673
Published ON
Oct, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cardiac Marker Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback